Giusti M, Lomeo A, Mazzocchi G, Mignone D, Sessarego P, Monachesi M, Giordano G
J Endocrinol Invest. 1985 Jun;8(3):203-6. doi: 10.1007/BF03348478.
GRF (1-40), dopamine (DA), DA plus GRF and placebo were administered to 6 acromegalic patients. The GRF administration induced a highly variable GH release (GH delta % 167.3 +/- 21.4; mean +/- SE). GRF did not provoke any change in PRL serum levels. During simultaneous GRF and DA administration GH release was found to be reduced (GH delta % 80.2 +/- 17.8) compared to that observed for a corresponding period of time after GRF alone (p less than 0.05). Our data underscore that in acromegaly the DA tonus inhibits GH secretion after GRF by acting directly at the pituitary level.
向6例肢端肥大症患者分别给予生长激素释放因子(GRF)(1 - 40)、多巴胺(DA)、多巴胺加生长激素释放因子以及安慰剂。给予生长激素释放因子可诱导生长激素释放高度可变(生长激素变化百分比为167.3±21.4;均值±标准误)。生长激素释放因子未引起催乳素血清水平的任何变化。与单独给予生长激素释放因子后相应时间段相比,同时给予生长激素释放因子和多巴胺时生长激素释放减少(生长激素变化百分比为80.2±17.8)(P<0.05)。我们的数据强调,在肢端肥大症中,多巴胺张力通过直接作用于垂体水平来抑制生长激素释放因子后的生长激素分泌。